2024 ValAct Meeting - Session 9H: IUL – Hot Product – Valuation Actuaries Beware! 8.28.24 Recording

Indexed universal life (IUL) continues to be the most popular universal life (UL) product with sales reaching $1B in Q4 2023, according to LIMRA. There is little long term experience for IUL and many companies value and model IUL just like UL, but there are material potential differences that need to be considered for valuation and projection purposes. Presenters will discuss key risks and differences between IUL and UL relating to policyholder behavior and how to value, project, monitor and manage those risks to avoid repeating misestimates of the past. Presenters will also discuss broader life assumption risks such as mortality and yearly renewable term (YRT) reinsurance risk. Attendees will learn about options on how to potentially address underperforming blocks of IUL and will obtain an improved perspective on the risks of IUL products and the differences versus UL and how to incorporate these differences into their valuation and projection exercises.